Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318150 | 0.88 | HTR4 (0.53) | HTR4CHRM1CHRM2CHRM4CHRM3 | |
| SCHEMBL14382457 | 0.86 | HTR4 (0.44) | HTR4HTR3A | |
| SCHEMBL2332701 | 0.82 | HTR4 (0.51) | HTR4 | |
| Hydrochloric Acid SCHEMBL5631883 | 0.81 | HTR4 (0.50) | HTR4 | |
| SCHEMBL17978225 | 0.81 | HTR4 (0.44) | HTR4HTR3A | |
| SCHEMBL5315555 | 0.80 | KDM4E (0.49) | HTR4 | |
| Hydrochloric Acid SCHEMBL5332277 | 0.80 | HTR4 (0.47) | HTR4HTR3A | |
| Succinic Acid SCHEMBL5632076 | 0.79 | HTR4 (0.47) | HTR4 | |
| SCHEMBL5315558 | 0.79 | HTR4 (0.41) | HTR4HTR3A | |
| SCHEMBL17978168 | 0.77 | HTR4 (0.46) | HTR4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | claimed |
| WO-2007096352-A1 | 5-AMINO-6-BROMO-N-{ [1- (TETRAHYDR0-2H-PYRAN-4-YLMETHYL) -4-PIPERIDINYL] METHYL}-3, 4 -DIHYDRO-2H-CHROMENE-8-CARBOXAMIDE AS 5-HT4 RECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | WO | claimed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232657-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| WO-2007096352-A1 | 5-AMINO-6-BROMO-N-{ [1- (TETRAHYDR0-2H-PYRAN-4-YLMETHYL) -4-PIPERIDINYL] METHYL}-3, 4 -DIHYDRO-2H-CHROMENE-8-CARBOXAMIDE AS 5-HT4 RECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096352-A1 | 5-AMINO-6-BROMO-N-{ [1- (TETRAHYDR0-2H-PYRAN-4-YLMETHYL) -4-PIPERIDINYL] METHYL}-3, 4 -DIHYDRO-2H-CHROMENE-8-CARBOXAMIDE AS 5-HT4 RECEPTOR AGONIST | GLAXO GROUP LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007068739-A1 | 4-AMINO-BENZAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL, NEUROLOGICAL AND CARDIOVASCULAR DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232657-A1 | NOVEL COMPOUNDS | HTR4, HTR5A, HTR6 | PIM1 4048/4885PIM2 3517/4885HTR4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.